# US 2023/0404912 A1 · Compositions and methods for the treatment of presbyopia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404912 A1
- Document ID: US20230404912A1
- Status: Published application
- Kind: A1
- Application number: 18/241,733
- Filed: 2023-09-01
- Published: 2023-12-21
- Earliest claimed: 2015-06-18
- Assignees: Lenz Therapeutics, Inc.
- Applicants: Lenz Therapeutics, Inc.
- Inventors: Gerald HORN
- Web page: https://patentgrep.com/patent/US20230404912A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 27/02: Ophthalmic agents
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

## Claims

### Claim 1

A method of inhibiting or reducing ciliary spasm or pain in a subject, said method comprising administering a polyol to said subject in combination with aceclidine, wherein said subject experiences greater ciliary spasm or pain when otherwise similarly administered aceclidine in an absence of said polyol.

### Claim 2 (depends on 1)

The method of claim 1, wherein said method does not comprise administering a physiologically significant amount of tropicamide.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administering less than about 0.02% tropicamide in combination with said aceclidine and said polyol.

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering a non-ionic surfactant in combination with said aceclidine and said polyol.

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering a viscosity agent in combination with said aceclidine and said polyol.

### Claim 6 (depends on 1)

The method of claim 1, wherein said polyol and said aceclidine are administered together in a combined composition.

### Claim 7 (depends on 6)

The method of claim 6, wherein, prior to administering to said subject, said combined composition is lyophilized.

### Claim 8 (depends on 1)

The method of claim 1, wherein said subject is being treated for presbyopia.

### Claim 9 (depends on 1)

The method of claim 1, wherein said method improves vision of said subject by at least 1.5 lines of visual acuity.

### Claim 10 (depends on 1)

The method of claim 1, wherein said method improves vision of said subject by at least 5% compared to similarly administered aceclidine in the absence of said polyol.

### Claim 11 (depends on 1)

The method of claim 1, wherein said method improves vision of said subject for at least 4 hours.

### Claim 12 (depends on 1)

The method of claim 1, wherein said method improves vision of said subject by at least 5% and reduces ciliary spasm by at least 5% compared to similarly administered aceclidine in the absence of said polyol.

### Claim 13 (depends on 12)

The method of claim 12, wherein said method improves vision of said subject by at least 1.5 lines of visual acuity for at least 4 hours.

### Claim 14 (depends on 1)

The method of claim 1, wherein said aceclidine is administered in a composition where an amount of said aceclidine is not greater than about 2% w/v.
